Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
About the Study
NOTE: This study is now closed.
This is a phase II study looking at different treatment combinations for men with , castration resistant cancer (mCRPC) to see which is most effective for improving progression free survival (keeping the cancer from progressing). The study will include testing for genes within the tumor to determine eligibility for the study.
The study multiple treatment arms. Patients with tumors that have , and/or mutations or defects will be randomly assigned to one of the treatment arms of the study. Patients with tumors that have mutations in other repair genes including FANCA, , RAD51, ERCC3, MRE11, , MLH3, CDK12, , HDAC2, ATR, , GEN1, , , , or FAM175A will be assigned to Arm IV with single agent .
This Study is Open To:
NOTE: This study is now closed.
This Study is NOT Open To:
NOTE: This study is now closed.